MX2018007517A - Compuestos triciclicos y composiciones como inhibidores de quinasa. - Google Patents

Compuestos triciclicos y composiciones como inhibidores de quinasa.

Info

Publication number
MX2018007517A
MX2018007517A MX2018007517A MX2018007517A MX2018007517A MX 2018007517 A MX2018007517 A MX 2018007517A MX 2018007517 A MX2018007517 A MX 2018007517A MX 2018007517 A MX2018007517 A MX 2018007517A MX 2018007517 A MX2018007517 A MX 2018007517A
Authority
MX
Mexico
Prior art keywords
compositions
compounds
kinase inhibitors
tricyclic compounds
therapeutic
Prior art date
Application number
MX2018007517A
Other languages
English (en)
Inventor
Patrick Dillon Michael
Robinson Richard
T Burger Matthew
John AVERSA Robert
A Dineen Thomas Jr
Karki Rajesh
Ramurthy Savithri
Rauniyar Vivek
James Sarver Patrick
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2018007517A publication Critical patent/MX2018007517A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring

Abstract

La presente invención proporciona compuestos de la fórmula (A): (ver Fórmula) como se describe en la presente y sus sales y usos terapéuticos de estos compuestos para el tratamiento de trastornos asociados con la actividad de la Raf quinasa. La invención también proporciona composiciones farmacéuticas que comprenden estos compuestos y composiciones que comprenden estos compuestos y un coagente terapéutico y métodos de uso de las composiciones y combinaciones para tratar condiciones que incluyen cánceres.
MX2018007517A 2015-12-18 2016-12-15 Compuestos triciclicos y composiciones como inhibidores de quinasa. MX2018007517A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562269252P 2015-12-18 2015-12-18
PCT/IB2016/057633 WO2017103824A1 (en) 2015-12-18 2016-12-15 Tricyclic compounds and compositions as kinase inhibitors

Publications (1)

Publication Number Publication Date
MX2018007517A true MX2018007517A (es) 2018-08-01

Family

ID=57570893

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018007517A MX2018007517A (es) 2015-12-18 2016-12-15 Compuestos triciclicos y composiciones como inhibidores de quinasa.

Country Status (12)

Country Link
US (1) US10377770B2 (es)
EP (1) EP3390404B1 (es)
JP (1) JP6847954B2 (es)
KR (1) KR20180095595A (es)
CN (1) CN108699065B (es)
AU (1) AU2016371387B2 (es)
BR (1) BR112018012292A2 (es)
CA (1) CA3008098A1 (es)
EA (1) EA201891439A1 (es)
ES (1) ES2892624T3 (es)
MX (1) MX2018007517A (es)
WO (1) WO2017103824A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107698586B (zh) * 2017-09-19 2020-02-07 广州大学 一种由铜化合物催化制备吡啶并喹唑啉酮类化合物的方法
CN113264945B (zh) * 2020-02-17 2022-11-22 江苏恒瑞医药股份有限公司 一种螺环衍生物、其制备方法及其在医药上的应用
CN113429440B (zh) * 2020-03-23 2023-05-12 江苏恒瑞医药股份有限公司 一种螺环化合物的前药、其制备方法及其在医药上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2568756A1 (en) * 2004-06-15 2005-12-29 Astrazeneca Ab Substituted quinazolones as anti-cancer agents
EP1871773A1 (en) * 2005-03-17 2008-01-02 Novartis AG N-[3-(1-amino-5,6,7,8-tetrahydro-2,4,4b-triazafluoren-9-yl)-phenyl]benzamides as tyrosine/threonine kinase inhibitors, in particular b-raf kinase
EP2027123B1 (en) 2006-05-11 2011-02-23 Irm Llc Compounds and compositions as protein kinase inhibitors
US9180127B2 (en) 2009-12-29 2015-11-10 Dana-Farber Cancer Institute, Inc. Type II Raf kinase inhibitors
SG188302A1 (en) * 2010-09-16 2013-04-30 Hutchison Medipharma Ltd Fused heteroaryls and their uses

Also Published As

Publication number Publication date
EP3390404A1 (en) 2018-10-24
AU2016371387B2 (en) 2019-11-14
EA201891439A1 (ru) 2018-12-28
BR112018012292A2 (pt) 2018-11-27
US10377770B2 (en) 2019-08-13
AU2016371387A1 (en) 2018-07-05
KR20180095595A (ko) 2018-08-27
EP3390404B1 (en) 2021-07-21
JP2018537508A (ja) 2018-12-20
CA3008098A1 (en) 2017-06-22
WO2017103824A1 (en) 2017-06-22
ES2892624T3 (es) 2022-02-04
CN108699065A (zh) 2018-10-23
JP6847954B2 (ja) 2021-03-24
CN108699065B (zh) 2021-08-31
US20180362542A1 (en) 2018-12-20

Similar Documents

Publication Publication Date Title
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12018500040A1 (en) Indazole and azaindazole compounds as irak-4 inhibitors
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
PH12018502102A1 (en) Pyrrolotriazine compounds as tam inhibitors
PH12017500416A1 (en) Compounds and compositions as raf kinase inhibitors
PH12015502116A1 (en) Biaryl amide compounds as kinase inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
MX2016003486A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
PH12016501160A1 (en) Isochromene derivatives as phosphoinositide 3-kinases inhibitors
PH12017500401A1 (en) Therapeutic compounds as inhibitors of the orexin-1 receptor
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MX2017011277A (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
MX2020009966A (es) Formas de dosificacion y usos terapeuticos de la l-4-cloro quinurenina.
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
EA201792445A1 (ru) Новые амидогетероарилароилгидразидэтины
MX2015015290A (es) Compuestos furanona como inhibidores de quinasa.
MY192305A (en) Bipyrazole derivatives as jak inhibitors